Skip to search formSkip to main contentSkip to account menu

J 107088

Known as: J-107088, J107088 
National Institutes of Health

Related topics

Related topics

2 relations
PHA-782615

Broader (1)

edotecarin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors
Edotecarin (J-107088), a novel inhibitor of topoisomerase I has an additive effect on colon cell lines (HCT-116) when combined… 
2007
2007
Antitumor activity of edotecarin in breast carcinoma models
PurposeEdotecarin (J-107088, formerly ED-749) is a potent indolocarbazole topoisomerase-I inhibitor that has the potential to… 
2006
2006
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
PurposeTo assess the maximum tolerated dose, safety, and pharmacokinetic (PK) profile of escalating doses of the novel… 
2006
2006
Antitumor Efficacy of Edotecarin as a Single Agent and in Combination with Chemotherapy Agents in a Xenograft Model
The novel indolocarbazole edotecarin (J-107088, formerly ED-749) differs from other topoisomerase I inhibitors both… 
2005
2005
Pharmacokinetics (PK) of edotecarin (J-107088), a topoisomerase I inhibitor, in patients with metastatic breast cancer (mBC) or glioblastoma multiforme (GBM)
2073 Background: Edotecarin is an indolocarbazole topoisomerase I inhibitor currently under clinical development for cancer… 
2003
2003
Plasma stability of two glycosyl indolocarbazole antitumor agents.
2001
2001
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H…
Abstract. Purpose: The in vivo antitumor activity of a novel topoisomerase I inhibitor, J-107088, was tested in athymic nude mice… 
Review
2000
Review
2000
Preclinical and Clinical Trials of Topoisomerase Inhibitors
Abstract: CPT‐11, developed by Yakult Honsha, has achieved the position of standard chemotherapy for colorectal cancer in the… 
Highly Cited
1999
Highly Cited
1999
Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
J-107088 [6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a… 
1999
1999
In vivo Anti‐tumor Activity of a Novel Indolocarbazole Compound, J‐107088, on Murine and Human Tumors Transplanted into Mice
J‐107088 (6‐N‐(1‐hydroxymethyl‐2‐hydroxy)ethylamino‐12,13‐dihydro‐2,10‐dihydroxy‐13‐(β‐D‐glu‐copyranosyl)‐5H‐indolo[2,3‐a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)